Navigation Links
KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
Date:11/13/2008

and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive responses to the Company's sales, marketing and strategic efforts, including the introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries; (13) risks that the Company may not ultimately prevail in litigation, including challenges to our intellectual property rights by actual or potential competitors or to our ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against products sold by the Company or its subsidiaries including without limitation the litigation and claims referred to in the above-referenced Form 12b-25 and in Note 16 of the Notes to the Consolidated Financial Statements in the Company's Form 10-Q for the quarter ended June 30, 2008; (14) the possibility that KV's current estimates of the financial effect of certain previously announced product recalls could prove to be incorrect; (15) whether any product recalls or product introductions results in litigation, agency action or material damages; (16) the possibility that the findings of the Audit Committee inquiry referenced in the Company's Form 10-Q for the quarter ended June 30, 2008, and/or finalizing and/or filing of the Company's financial statements for the first and second quarters of fiscal 2009, could have a material impact on the Company's previously reported or future financial results; (17) the possibility that the auction rate securities held by the Company may not return to liquidity or at their face value; and (18) the risks detailed from time-to-time in the Company's filings with the Securities a
'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Texas (PRWEB) July 14, 2014 The ... encourage investment in the Global Mobile Health Solutions market. ... in the Health IT for Economic and Clinical Health ... February 2009. , Analysts forecast the Global Mobile ... of 34.88 percent over the period 2013-2018. According to ...
(Date:7/14/2014)... The report “Intelligent Building Automation Technologies ... Safety, Facility Management], IT Technologies & Industry Verticals ... - 2019)” defines and segments the IBAS market ... forecasting of revenues. The report also identifies the ... impacting it, along with the technology roadmap and ...
(Date:7/14/2014)... Physical fitness may buffer some of the adverse health ... study by researchers from the American Cancer Society, The ... appears in the journal Mayo Clinic Proceeding s, ... obesity and blood markers associated with cardiovascular disease is ... Sedentary behavior has been linked to an increase risk ...
(Date:7/14/2014)... TX (PRWEB) July 14, 2014 ... heart valves market in Americas. The analysis includes ... the 2007–2020 period and key company share data ... US, Canada, Brazil and Mexico. It uses data ... secondary research and in-house analysis. , Scope, ...
(Date:7/14/2014)... Secure Decisions, a leading provider of ... the Software Assurance Marketplace (SWAMP) to build a powerful ... drives everyday life. , The SWAMP, implemented by a ... Morgridge Institute for Research, is funded by the Department ... practices by building a free facility with a diverse ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... made him the last of his line, researchers say ... powerful Habsburg royal family ruled Spain for centuries until the ... , Now, a new study suggests the reason for their ... and their unfortunate habit of marrying their own relatives. ...
... the highest level of excellence, achieving ASQ CQI Certifications. , ... ... Board of the American Society for Quality is pleased to announce ... completed the requirements to be named an ASQ-Certified Quality Inspector (ASQ ...
... 8 Saints Mary and Elizabeth Medical Center, 2233 ... Blue Cross and Blue Shield of Illinois, Childhood Health ... for children at risk for obesity and diabetes. This ... Obesity is an epidemic in the United States. Since ...
... 8 This Sunday, individuals all over the ... the women who gave them life: their mothers. While people ... the International Breast Milk Project (IBMP) hopes to inspire some ... organization that helps mothers in the United States send their ...
... Protect Patients and Consumers ROCKVILLE, Md., May 8 ... substantial increase in funding for the Food and ... budget. Following the Obama administration,s voiced support for ... increase the agency,s ability to protect American patients ...
... May 8 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2009 third quarter financial results. The ... on Thursday, May 14, 2009 at 4:30 p.m. Eastern Time ... Company,s website at www.pro-dex.com . Mark ...
Cached Medicine News:Health News:Inbreeding May Have Doomed Spain's Habsburg Dynasty 2Health News:Inbreeding May Have Doomed Spain's Habsburg Dynasty 3Health News:Clinical Instrument Repair Consultants Receive ASQ-Certified Quality Inspector 2Health News:Blue Cross and Blue Shield Funds Diabetes Education at Saints Mary and Elizabeth Medical Center 2Health News:International Breast Milk Project Helps Mothers Worldwide 2Health News:USP Applauds President's Budget Support for FDA 2Health News:Pro-Dex, Inc. Announces Fiscal 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
(Date:7/13/2014)... July 13, 2014  Eli Lilly and Company ... from its non-clinical study in genetically engineered mice ... the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE ... more effective in removing clumps of amyloid-beta protein ... thought to lead to Alzheimer,s disease (AD) – ...
(Date:7/11/2014)... , July 11, 2014 The consumer ... evolving across industry sectors to better identify winning ... ways to engage with and understand consumers, as ... and make critical purchasing decisions. ... Practices, LLC, one area where organizations can observe ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Technologies Transforming Consumer Marketing Research Playbook 2